Table 3 Characteristics of drugs under patent challenges sorted by challenge year
From: Patenting and patent challenges in South Korea after introducing a patent linkage system
Challenge year | 2007 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | Total |
|---|---|---|---|---|---|---|---|---|---|
Number of drugs (N) | 1 | 2 | 6 | 1 | 63 | 11 | 6 | 5 | 95 |
Drug type | |||||||||
Chemical | 1 | 2 | 6 | 0 | 63 | 11 | 6 | 5 | 94 |
Biologic | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
Statutory exclusivity | |||||||||
No | 1 | 1 | 2 | 0 | 5 | 7 | 4 | 1 | 21 |
Yes | 0 | 1 | 4 | 1 | 58 | 4 | 2 | 4 | 74 |
Manufacturer type | |||||||||
Domestic | 1 | 1 | 4 | 0 | 9 | 3 | 1 | 1 | 20 |
Foreign | 0 | 1 | 2 | 1 | 54 | 8 | 5 | 4 | 75 |
Administration | |||||||||
Oral | 1 | 1 | 6 | 0 | 55 | 10 | 6 | 4 | 83 |
Injection | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 1 | 4 |
Others | 0 | 1 | 0 | 0 | 6 | 1 | 0 | 0 | 8 |
ATC classification | |||||||||
J/L | 0 | 0 | 2 | 1 | 9 | 1 | 0 | 0 | 13 |
A/B/C | 0 | 0 | 3 | 0 | 37 | 4 | 4 | 4 | 52 |
M/N | 1 | 1 | 0 | 0 | 6 | 4 | 0 | 0 | 12 |
Others | 0 | 1 | 1 | 0 | 11 | 2 | 2 | 1 | 18 |